logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Promoting R&D, equity, access and measurement of health outcomes, priorities for the pharmaceutical industry in the fight against cancer

Oncology is one of the key issues on the health agenda that Spain will take to the Presidency of the Council of the European Union in the second half of 2023

At a workshop organised by Farmaindustria and the CDTI, member companies learn about the development of the ‘Cancer Mission’, a pillar of the Horizon Europe research framework programme

Taller del CDTI y Farmaindustria sobre los avances de la 'Misión Cáncer'

Source: farmaindustria.es

Cancer is the leading cause of death for Europeans under the age of 65 and forecasts warn that it will affect half of the population in their lifetime. The fight against this disease is one of the key issues on the health agenda that Spain will take to the Presidency of the Council of the European Union, which it will hold in the second half of 2023.

It will be an opportunity to address the importance of biomedical innovation in this area and to make progress on the European initiatives already underway in this regard. One of these is the Cancer Mission, one of the five pillars of Horizon Europe, the framework programme for research and innovation in the region for the period 2021-2027. “This mission aims to advance coordinated R&D and innovation projects to improve the lives of more than three million Europeans by 2030. The aim is to promote prevention, diagnosis, better treatments for greater survival and quality of life for patients and their families,” says Amelia Martín Uranga, associate director of Clinical Research and Translational Medicine at Farmaindustria.

To gain an in-depth understanding of the characteristics of this mission and the possibilities it presents for the development of new projects, Farmaindustria organised a session on Tuesday with around 40 pharmaceutical companies together with the Centre for the Development of Industrial Technology (CDTI). Marta Quintanilla, the Spanish representative of the Health Cluster in Horizon Europe, the Innovative Health Initiative (IHI) and the subgroup of the Cancer Mission, was in charge of explaining the implementation of this project from the CDTI. The main objectives of this mission are to identify and exploit R&D&I results to accelerate their transfer to public health and clinical practice, establish a common strategic agenda, create a link between R&D&I and the development of European policies and increase intersectoral collaboration in oncology.

The CDTI representative stressed that there are four cross-cutting priorities for the projects: equality, innovation, paediatric tumours and personalised medicine. She added that projects should, in general, involve patients and carers and other disciplines, and increase the focus on tangible results that generate social impact and healthcare-oriented solutions.

In addition to Mission Cancer, Europe launched in 2021 the European Plan to Combat Cancer, with the aim of helping Member States to improve control and care in this pathology and to curb inequalities. Thus, Farmaindustria considers it a priority to adopt measures aimed at guaranteeing equal access to prevention and treatment for all European citizens. This is a problem in the EU and also within the Member States, as reflected in the data from the European Cancer Inequalities Register, produced by the Organisation for Economic Co-operation and Development (OECD).

This report indicates that in Spain the path from the approval of cancer drugs to their effective prescription is complex and that there are major differences between autonomous communities. “Working on the decentralisation of clinical trials – currently concentrated in Madrid and Catalonia – will benefit professionals and the health system and, above all, patients,” stresses Martín Uranga.

In addition to improving patient access to new drugs, it is also a priority to speed up patient participation in clinical trials. This can be achieved through decentralisation, the promotion of cross-border clinical trials within the EU or the full implementation of the new European Clinical Trials Regulation. Sharing information and exploiting the measurement of health data (the so-called real world data) in accordance with ethical guarantees and the regulation of personal data protection are other priorities that the industry considers essential to address during the upcoming Spanish Presidency of the Council of the EU. In order to make progress in the fight against cancer, it would also be important to consider the adoption of additional incentives to attract research to critical fields such as childhood cancer and the development of comprehensive cancer centres where the pathology is addressed from an integrated healthcare, research and teaching perspective.

The pharmaceutical industry already conveyed its priorities for the six months of the Spanish Presidency to the Government during the high-level meeting held in December with the Government, which marked the launch of the Strategic Plan for the Pharmaceutical Industry. The challenge lies in promoting a biomedical research ecosystem on the continent, based on the protection of intellectual property and flexible and equitable access to innovation, and more resilient drug production and supply chains that make Spain a hub for innovation and drug manufacturing within the EU.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.